Document:

Filed by Automated Filing Services Inc. (604) 609-0244 - ImVisioN Therapeutics Inc. - Exhibit 10.18

EXHIBIT 10.18 

 

 

 

Consultancy Agreement 

 

 

Between

 

ImVisioN GmbH,
located at Feodor-Lynen-Str. 5, 30625
Hannover, 

- hereinafter referred as "ImVisioN"-, 

and 

SK Research AG, Medical Development and Consulting,
Rötelstrasse 20, 8006 Zürich, 

- hereinafter referred as ”SK” -. 

Represented by PD Dr. Thomas Kündig 

- hereinafter referred to as “Consultant” -

WHEREAS, ImVisioN is a biotechnology company focused on the
development of immuno-therapeutics based on its proprietary MAT
(Modulary-Antigen-Transporter Molecules) technology platform to treat allergic
diseases. 

WHEREAS, Consultant is an employee of the Universitätsspital
Zürich and has professional experience in immunology, allergology, as well as in
preclinical and clinical evaluation of specific allergen immunotherapy. 

WHEREAS, ImVisioN desires to engage the services of Consultant
as an independent Consultant to assist ImVisioN, and Consultant desires to be so
engaged. 

NOW, THEREFORE in consideration of the above facts and the
mutual promises set forth in this Agreement, the parties agree as follows: 

	1. 	
      Appointment

	 	 
		
      ImVisioN hereby appoints Consultant to act as a
      SK-employed, independent business Consultant to assist ImVisioN with the
      development of immuno- therapeutics based on its proprietary MAT
      technology platform to treat allergic diseases in accordance with the
      terms of this Agreement. Consultant hereby accepts such
  appointment.

	 	 
	2. 	
      Scope of Services

	 	 
	2.1 	
      Consultant shall assist ImVisioN by providing support
      with regard to preclinical and clinical evaluation of its MAT-based
      product candidates. Consultant agrees to render the services under the
      terms and conditions set forth in this Agreement.

	 	 
		
      Consultant agrees to complete the services under this
      Agreement in a satisfactory manner.

	 	 
	2.2 	
      The advice of Consultant shall be supplied orally to the
      Management of ImVisioN and upon request of ImVisioN, the Consultant will
      submit written reports on specific issues.

	 	 
	2.3 	
      Consultant shall have no power of attorney for ImVisioN.
      In particular, he shall not be entitled to or undertake any encashments
      for ImVisioN. Consultant shall not and under no circumstance act on behalf
      of ImVisioN. Consultant shall clearly communicate to any third party
      contacted in his function as Consultant to ImVisioN his legal status in
      relation to ImVisioN.

	 	 
	2.4 	
      Consultant shall provide consulting services of up to 6
      (six) days per months to the Company. Any additional consulting services
      shall be mutually agreed by the parties.

	
3. 		
Information duties

	
	 	 
	
3.1 		
Consultant shall regularly keep ImVisioN informed as to the progress and status of Consultant’s activities under this Agreement.

	
	 	 
	
3.2 		
ImVisioN shall provide Consultant with all relevant information and documents required for the performance of Consultant’s services.

	
	 	 
	
4. 		
Fees

	
	 	 
	
4.1 		
As a payment for the services under this Agreement, Consultant shall be entitled to a monthly consulting fee of € 6.000 (plus VAT, if applicable). This monthly consulting fee shall compensate the Consultant for consulting
services of up to 6 days per calendar month. In case the services requested by ImVisioN and provided by Consultant exceed 6 (six) days for a certain calendar month over a period of 6 (six) consecutive months, the Consultant shall receive an extra
consulting fee of € 1.000 (plus VAT, if applicable) per consulting day for every consulting day exceeding 6 (six) days per month. In such case, Consultant shall submit to ImVisioN an invoice for such extra consulting services. Except as set
forth in this Agreement, Consultant shall not be entitled to any other compensation or benefits for his services to ImVisioN.

	
	 	 
	
4.2 		
Reasonable travel costs, costs for accommodation, meal costs and other expenses which the Consultant incurs in performing his consultancy services under this Agreement shall be reimbursed by ImVisioN after submission of an expense
report with corresponding bills at the end of each calendar month.

	
	 	 
	
4.3 		
Any and all tax liabilities, social security charges or levies of a similar nature arising out of or in connection with the Consultant’s services to ImVisioN hereunder shall be borne exclusively by the Consultant.

	
	 	 
	
4.4 		
Payments shall be made to the bank account designated by SK and notified to ImVisioN (Zürcher Kantonalbank, Konto Nr. 1100-0487.771).

	
	 	 
	
5. 		
Present Employment:

	
	 	 
		
ImVisioN acknowledges and agrees that Consultant is currently employed by and/or is member of the faculty of a university or a non-profit research institution (“Employer”). Notwithstanding anything in this Agreement to
the contrary, during the period of this Agreement, Consultant being member of the faculty of a university and/or non-profit research institution shall not be deemed a breach of SK’s obligations under this Agreement.

	

	
6. 		
Conflict with Employment:

	
	 	 
		
ImVisioN recognizes and agrees that SK’s obligations and performance of its duties under this Agreement are limited by the fact that, in connection with Consultant’s employment by Employer, Consultant’s primary
responsibilities are to the Employer and that Consultant is subject to the Employer's policies, including policies concerning consulting, conflicts of interest and intellectual property. SK warrants that Consultant is permitted to be employed by SK
for purposes of SK’s performance under this Agreement, and that this is not inconsistent with Consultant’s present employment by Employer or other contractual agreements.

	
	 	 
	
7. 		
Exclusivity for the Project

	
	 	 
		
SK agrees that during the period in which SK provides Consultant’s services to ImVisioN, Consultant will not, without ImVisioN’s express written consent, engage in any employment or activity (whether as an employee,
Consultant, adviser or otherwise) for a project that is both commercially directly competitive with and scientifically similar to ImVisioN’s projects for the development of immunotherapies for allergies based on the MAT technology
(“EXCLUSIVITY”). ImVisioN recognizes and agrees that Consultant may currently have certain agreements to perform consulting services for others that are directly competitive with and scientifically similar to ImVisioN’s project. SK
warrants that Consultant has discussed with ImVisioN all agreements relating to such projects of third parties prior to signing this Agreement, as listed in Appendix A.

	
	 	 
	
9. 		
Notification of Potential Conflict:

	
	 	 
		
If during the period of this Agreement, Consultant wishes to enter into any additional agreement or activity which might conflict with the EXCLUSIVITY, SK will submit an outline of the potentially conflicting project to ImVisioN
with a request to agree that SK provide services to the conflicting project. ImVisioN will advise SK whether ImVisioN agrees that SK provide services for the potentially conflicting project, which agreement shall not be unreasonably withheld.

	
	 	 
	
10. 		
Conflict of Interest:

	
	 	 
		
If SK or Consultant have a conflict of interest, or a potential conflict of interest, with respect to any matter presented at a meeting of ImVisioN or in other interactions with ImVisioN, SK or Consultant will state such, and
excuse from the discussion of such matter.

	

	11. 	
      Confidential Information

	 	 	 
	11.1 	
      In consideration of, and reliance upon, the covenants of
      Consultant and ImVisioN herein contained, the parties have or will
      disclose to each other certain information (hereinafter referred to as
      "Confidential Information"), including, without limitation,
      information concerning future or proposed products, financial performance
      and projections, customers, employees, contracts, strategic relationships,
      marketing plans and business plans and other information. All documents,
      disclosures and written or oral statements disclosed by a party (the
      "Disclosing Party") to the other party (the "Receiving
      Party") shall be deemed "Confidential Information" if clearly marked
      so. Except as provided herein, "Confidential Information" shall include,
      without limitation, proprietary, technical, marketing, operating,
      performance, cost, business pricing policies, programs, inventions,
      discoveries, trade secrets, techniques, processes, source code, unlinked
      object modules, computer programming techniques, and all record bearing
      media containing or disclosing such information and techniques disclosed
      pursuant to this Agreement.

	 	
       
	
       

		
      The Agreement itself and its content, as well as the
      identity of the parties shall be considered Confidential Information as
      well.

	 	
       
	
       

	11.2 	
      The obligations of this Agreement hereof shall not apply
      to any information if:

	 	
       
	
       

		
      a) 
	
      it was in the public domain at the time of communication
      to the Receiving Party or is later placed in the public domain by the
      Disclosing Party;

	 	
       
	
       

		
      b) 
	
      it entered the public domain through no fault of the
      Receiving Party subsequent to the time of disclosure hereunder to the
      Receiving Party;

	 	
       
	
       

		
      c) 
	
      it was in the Receiving Party's possession free of any
      obligation of confidence prior to disclosure hereunder.

	 	
       
	
       

	11.3 	
      a) 
	
      The Receiving Party shall not disclose, publish or
      communicate the Confidential Information to any third party without the
      prior written consent of the Disclosing Party.

	 	
       
	
       

		
      b) 
	
      The Receiving Party shall not use the Confidential
      Information nor circulate it within its own organisation except to the
      extent necessary or desirable for negotiations, discussions and
      consultations with personnel or authorized representatives of the parties,
      relating to the purposes of this Agreement.

	 	
       
	
       

		
      c) 
	
      The Receiving Party shall use its best efforts to prevent
      inadvertent disclosure of the Confidential Information to unauthorized
      personnel or to any other third party, including establishing and
      monitoring internal procedures regarding the Confidential Information
      which are at least as protective as the protection the Receiving Party
      affords its own Confidential Information. The Receiving Party shall
      immediately notify the Disclosing Party if the Confidential Information is
      used, distributed, or communicated in a manner not authorized under this
      Agreement.

	 	d) 	
      Upon demand or, if not otherwise demanded, upon the
      termination of such project or purposes, the Confidential Information and
      all copies thereof and notes made therefrom shall be immediately destroyed
      by the Receiving Party or returned to the Disclosing Party. If destroyed,
      the Receiving Party shall certify in writing to the Disclosing Party that
      all such information, including all copies, has been
  destroyed.

	12. 	
      Intellectual Property

	 	 
		
      Intellectual property invented, created, written,
      developed, or produced as a result of Consultant's consulting services to
      ImVisioN pursuant to this Agreement, whether produced by the Consultant or
      any of its/his employees or agents while working for ImVisioN under this
      Agreement, is and shall be the sole property of ImVisioN. "Intellectual
      Property" includes any inventions, patents, trademarks, copyrights,
      software programs or developments or enhancements, ideas, creations,
      articles and any similar property. Consultant shall promptly provide
      ImVisioN, whether during or after the term of this Agreement, with those
      documents and signatures reasonably required by ImVisioN to vest ownership
      of the Intellectual Property in ImVisioN, and Consultant agrees to take
      any and all action reasonably necessary to vest such ownership in
      ImVisioN. ImVisioN alone has the right to use, sell, patent or license its
      Intellectual Property.

	 	 
	13. 	
      Term, Termination

	 	 
		
      This Consultancy Agreement shall become effective at the
      beginning of the month following the transfer of 100 % of the shares of
      ImVisioN to Nextech Ventures LP and shall be concluded for an indefinite
      period of time, provided, however, that this Agreement may be regularly
      terminated by either party on one month’s notice with effect to the end of
      a calendar month. The right to terminate this Consultancy Agreement
      without prior notice for serious reasons remains unaffected for both
      parties. Termination of this Agreement must be made in writing. ImVisioN
      shall inform the Consultant as soon as its shares have been transferred in
      accordance with the first sentence above.

	 	 
	14. 	
      Assignment

	 	 
		
      This Agreement is personal to the Consultant and he shall
      not be entitled to assign, delegate or subcontract his obligations
      hereunder to any third party without prior written consent of
    ImVisioN.

	 	 
	15. 	
      Miscellaneous

	 	 
	15.1 	
      This Agreement contains the whole agreement between the
      parties relating to the subject matter of this Agreement at the date
      hereof. Any change or amendment

		
      to this Agreement requires written consent of the
      parties, including the amendment of this subsection.

	 	 
	15.2 	
      In the event that a provision or a part of a provision of
      this Agreement should be or become ineffective, this shall not affect the
      validity of the other provisions of this Agreement and of the Agreement on
      the whole. The parties hereby agree to replace the ineffective provision
      by an effective provision, representing the parties intention at the time
      of conclusion of this contract. The same shall apply in case of a gap
      within this Agreement.

	 	 
	15.3 	
      This agreement shall be governed and construed in
      accordance with the laws of the Federal Republic of Germany, without
      regard to its conflict of law provisions.

	Zürich. 	 	Hannover. 
	  	 	  
	SK Research AG 	 	ImVisioN GmbH 
	  	 	  
	/s/ T.
      Kündig 	 	/s/
      Martin Steiner 
	PD Dr. Thomas Kündig 	 	Dr. M. Steiner, CEO 
	 	 	 
	/s/ G.
      Senti 	 	 
    
	Dr. Gabriela Senti 	 	Dr. H. Rose, COOFiled by Automated Filing Services Inc. (604) 609-0244 - ImVisioN Therapeutics Inc. - Exhibit 10.19

	  	  	EXHIBIT 10.19 
	  	  	  
	  	ImVisioN
    
	  	  	  
	ImVisioN GmbH Feodor-Lynen-Str. 5 D-30625 Hannover
    	  	  
	  	  	  
	  	  	  
	  	Ansprech- 	  
	  	partner: 	Martin Steiner 
	Therapeomic AG 	fon: 	(0511) 53 88 96-76 
	Prof. Tudor Arvinte 	fax: 	(0511) 53 88 96-66 
	c/o Biozentrum, University of Basel 	e-mail: 	m.steiner@imvision-therapeutics.com 
	Klingelbergstrasse 70 	  	  
	CH-4056 Basel 	  	  
	Switzerland 	  	  

Hannover, 17. August 2006 

Amendment of Collaboration Agreement dated February 2006

This is to confirm the intent of Therapeomics Inc. and ImVisioN
GmbH (the “Parties”) to amend their Collaboration Agreement (“Agreement”) dated
February 2005. 

The Parties agree that the Attachment A1, which is attached to
this Amendment shall become an integrated part of Attachment A of the Agreement.

The Parties further agree that the Attachment B1, which is
attached to this Amendment shall become an integrated part of Attachment B of
the Agreement. 

All other provisions of the Agreement remain in effect and
shall not be affected by this Amendment. 

This Amendment becomes effective on July 1st 2006 by
signature of both Parties: 

	Hannover, 17.8.2006 	Basel, 23.8.2006 
	  	  
	/s/ Martin
      Steiner 	/s/ Tudor Arvinte
	/s/ Horst
      Rose 	Therapeomic Inc. 
	ImVisioN GmbH 	  

Seite 2 

ATTACHMENT A1

I) Project goals:

	 	1) 	
      Develop special methods to study IVN201 binding to
      surfaces and aggregation proper- ties. These methods will be used for the
      development of a stable IVN201 formulation.

	 	2) 	
      Study IVN201 physico-chemical properties with focus on
      protein aggregation and bind- ing to surfaces.

	 	3) 	
      Perform a high-throughput-formulation screening study to
      find specific ingredients with beneficial effects in stabilizing IVN201 in
      solutions.

	 	4) 	
      Optimize the present IVN201 adjuvant formulation of
      ImVisioN.

	 	5) 	
      Based on the found best stabilizing conditions, develop
      IVN201 stable formulations. The target formulation will be a liquid
      formulation ready to use (including the best found ad- juvant); the second
      target formulation will be a stable freeze-dried formulation to be re-
      constituted with an aqueous solution and then mixed with the adjuvant
      prior to use.

II) Next collaboration steps: 

Experimental work will be performed in
the Therapeomic laboratories at Geneva University and at Biozentrum, University
of Basel.

The experimental work will have the
following phases: 

	1) 	
      Development of special methods to study the aqueous
      properties of IVN201 with focus on in vitro aggregation and binding to
      surfaces as well as of IVN201 interaction with Aluminium
    adjuvants

	 	 	 
		
      Understanding of the IVN201 properties is of crucial
      importance for the success of the pro- ject. To increase the success rate
      of the project we propose the development of following methods: a) field
      flow fractionation and b) circular dichroism.

	 	 	 
		a) 	
      Development of a Field Flow Fractionation (FFF) method
      to investigate the aggre- gation of INV201

Time frame: 1 month
  (July 2006) 

Milestone 1a-P2: Provide
  a Report on the developed FFF method to study the aggregation of INV201 in solutions
  

The FFF method(s) will be developed to
characterize the IVN201 aggregates and provide information on the molecular
weights of different protein aggregates. The FFF will also be used for the
stability study of the POC formulation. FFF will be a valuable tool in the
development of the IVN201 final formulations. 

Seite 3 

	 	b) 	
      Circular dichroism (CD) studies of the aggregation
      properties of INV201 in drug substance and in the drug
  product

Time frame: 2 months
  (July-August 2006) 

Milestone 1b-P2:
Provide a Report on CD studies on the INV201 aggregation states in solution, in
the drug substance and in the POC formulation 

CD will provide information on the
conformation of INV201 in different solutions and different aggregation states.
CD is of interest since it was used study the correct folding of the recombinant
folded major cat allergen Fel d 1 (Grönlund et al. 2003, J. Biol. Chem. 278,
40144-40151). The INV201 drug substance secondary structure as well as IINV201
in the POC formulation will be characterized.

Seite 4 

ATTACHMENT B1

Service Fees

In consideration for the performance of the work which will be
performed between July 2006 and August 2006 and which is described in Attachment
A1, ImVisioN shall pay to Therapeomic the amount stated in the present document;
the payments include VAT.

These amounts shall include any and all additional costs, such
as salaries, overhead, equipment, facilities and consumables, but not the active
pharmaceutical ingredients (IVN20 or special chemicals or used in the
formulations, or special columns used for analytical methods not developed by
Therapeomic), which shall be supplied by ImVisioN. Any project trip related
costs by Therapeomic employees should be paid by ImVisioN. 

This amount shall become due as follows: 

	- 	
      15’000 € (fifteen thousand Euro) upon successful
      completion of the Milestone 1a-P2 of the Attachment A2 (FFF method)
      and delivery of the related report; 

	 	 
	- 	
      15’000 € (fifteen thousand Euro) upon successful
      completion of the Milestone 1b-P2 of the Attachment A2-P2 (CD
      study) and delivery of the related report; 

Should the work from this Agreement lead to patentable
Inventions of improved stable ImVi-sioN formulations that will be patented by
ImVisioN, ImVisioN (or its licensee) should pay the following milestones to
Therapeomic: 

	 	1. 	
      50’000 € (fifty thousand Euro) within 30 days of filing a
      patent application upon any product or process resulting from the work
      performed by Therapeomic

	 	 	 
	 	2. 	
      100’000 € (hundred thousand Euro) within 30 days after
      first grant of such a patent in US, Switzerland, UK, Germany, Spain,
      Italy, France or any other EU country.

	 	 	 
	 	3. 	
      100’000 € (hundred thousand Euro) after the completed
      submissions by ImVisioN of the first new drug application (NDA) in US,
      Switzerland, UK, Germany, Spain, It- aly, France or any other EU country
      for a Patent Protected Pharmaceutical Product. With “Patent Protected
      Pharmaceutical Product” shall mean a pharmaceutical prod- uct which is
      covered by a patent (i) which patent is the direct result of an invention
      made by Therapeomic under this Agreement, (ii) which patent is granted to
      and owned by ImVisioN (or its licensees), and (iii) which pharmaceutical
      product repre- sents a dosage form or indication which is new compared to
      other products which exist on the market at the time of submission of the
      NDA.

	 	 	 
	 	4. 	
      300’000 € (three-hundred thousand Euro) after ImVisioN
      (or its licensee) obtains a marketing authorization in a first market
      using the Therapeomic formulation.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]